5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Background:

          Nivolumab is the human programmed cell death-1 (PD-1)-blocking antibody showing significant effect in many refractory cancers. However, little is known about its risks of hematological toxicities, rare but clinically serious and potentially life-threatening adverse events. We want to explore whether nivolumab can increase the risks of hematological toxicities compared with other immunotherapy or chemotherapy drugs.

          Method:

          The databases of PubMed, Embase, Web of science, and CNKI were searched. We used the medical subject heading terms “Nivolumab” plus keyword “Nivolumab” to search studies published from August 1990 to October 2021. For the included articles, we calculated the relative risks and the corresponding 95% confidence intervals (CIs) for the risks of anemia, neutropenia, and leukopenia in patients treated with nivolumab versus control drugs.

          Results:

          Five original articles on the nivolumab trials were identified with 2399 patients enrolled in this meta-analysis. The relative risks of anemia, neutropenia, and leukopenia were 0.343 (95% CI: 0.177–0.663; P = .001), 0.020 (95% CI: 0.008–0.053; P = .000), and 0.054 (95% CI: 0.015–0.191; P = .000), respectively.

          Conclusion:

          The PD-1 inhibitor-nivolumab did not increase the risk of anemia, neutropenia and leukopenia. It may enhance awareness about lower risks of hematological toxicities when choosing nivolumab as PD-1 inhibitor among clinicians.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

          The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

            Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

              New England Journal of Medicine, 373(2), 123-135
                Bookmark

                Author and article information

                Contributors
                Journal
                Medicine (Baltimore)
                Medicine (Baltimore)
                MD
                Medicine
                Lippincott Williams & Wilkins (Hagerstown, MD )
                0025-7974
                1536-5964
                30 December 2022
                30 December 2022
                : 101
                : 52
                : e32393
                Affiliations
                [a ] Department of Neurosurgery, General Hospital of Northern Theater Command, Shenyang, PR China
                [b ] Department of Neurology, No.926 Hospital, Joint Logistics Support Force of PLA, Yunnan, PR China
                [c ] Department of Officers, General Hospital of Northern Theater Command, Shenyang, PR China
                [d ] Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, PR China.
                Author notes
                * Correspondence: Hongna Guan, Department of Officers, General Hospital of Northern Theater Command, 83 Wenhua Road, Shenyang 110000, PR China ( hongnaguan@ 123456163.com ).
                Article
                00050
                10.1097/MD.0000000000032393
                9803513
                36596018
                52faf8cb-4d6b-48da-9744-2c5aeea54a0b
                Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

                This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 28 December 2021
                : 1 December 2022
                : 2 December 2022
                Categories
                5700
                Research Article
                Systematic Review and Meta-Analysis
                Custom metadata
                TRUE

                cancer,hematological toxicity,nivolumab, programmed cell death-1 (pd-1) inhibitor

                Comments

                Comment on this article